Clinical Characteristics and Prognosis of Adult Acute Myeloid Leukemia with NUP98 Gene Rearrangement.
10.19746/j.cnki.issn.1009-2137.2021.05.012
- Author:
Ning LU
1
;
Yi DING
1
;
Yong-Li WU
1
;
Li-Li WANG
1
;
Yu JING
1
;
Hong-Hua LI
1
;
Meng LI
2
Author Information
1. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
2. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China,E-mail: limeng2016@yeah.net.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Female;
Gene Rearrangement;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Male;
Middle Aged;
Nuclear Pore Complex Proteins/genetics*;
Prognosis;
Retrospective Studies;
Young Adult
- From:
Journal of Experimental Hematology
2021;29(5):1450-1455
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics, outcomes and prognosis of adult acute myeloid leukemia (AML) patients with NUP98 gene rearrangement.
METHODS:The clinical data of adult AML patients with NUP98 gene rearrangement from January 2015 to December 2019 were retrospectively analyzed, including clinical characteristics, laboratory examination, genetic anomaly, treatment strategy and survival.
RESULTS:A total of 15 patients with NUP98 gene rearrangement were detected in 410 adult AML patients (3.7%). The ratio of male to female among 15 patients was 1.1∶1, and the median age was 43 (17-76) years old. The main FAB types were M2 and M4/M5, and including one unclassified. According to the genetic prognosis, 11 cases were intermediate risk, while 4 cases were high risk. The main type of NUP98 gene rearrangement was NUP98-HOXA9 (13/15, 86.7%). 10 patients underwent next generation sequencing, in which 5 patients showed epigenetic gene mutations, 3 patients showed FLT3-ITD or WT1 mutations, and 2 patients showed no mutation. After induction therapy, 13 of 15 patients achieved complete remission（CR）. 7 of 8 patients with standard induction therapy achieved CR. 7 elder or intolerance patients with demethylation drug and chemotherapy all achieved CR. The median follow-up time was 28 months. The median OS of 15 the patients was 31.5 months (95% CI 10.7%-52.2%), and the median OS of the patients in non-allogeneic hematopoietic stem cell transplantation (Allo-HSCT) group was 18.5 months (95% CI 17.8%-19.1%). The median OS was not reached for the patients in the Allo-HSCT group.
CONCLUSION:Allo-HSCT can significantly improve the prognosis of AML patients with NUP98 rearrangement. NUP98 rearrangement can be accompanied by epigenetic gene mutations. For the elderly or patients who do not tolerate standard induction therapy, demethylation drugs combined with chemotherapy can achieve good outcomes.
